Last reviewed · How we verify
ABP 938
ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. Used for Osteoporosis in postmenopausal women, Bone loss in patients with hormone-sensitive prostate cancer receiving androgen deprivation therapy.
At a glance
| Generic name | ABP 938 |
|---|---|
| Also known as | PAVBLU™ |
| Sponsor | Amgen |
| Drug class | RANKL inhibitor |
| Target | RANKL |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | Phase 3 |
Mechanism of action
ABP 938 targets RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast differentiation and activation. By inhibiting RANKL signaling, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss. This mechanism is similar to denosumab, an established monoclonal antibody against RANKL.
Approved indications
- Osteoporosis in postmenopausal women
- Bone loss in patients with hormone-sensitive prostate cancer receiving androgen deprivation therapy
Common side effects
- Hypocalcemia
- Infections
- Osteonecrosis of the jaw
- Atypical femoral fractures
Key clinical trials
- A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] (PHASE3)
- A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP 938 CI brief — competitive landscape report
- ABP 938 updates RSS · CI watch RSS
- Amgen portfolio CI